ocugen
engages
kemwell
biopharma
cgmp
manufacture
malvern
globe
newswire
ocugen
nasdaq
ocgn
biopharmaceutical
company
focused
discovering
developing
commercializing
transformative
therapies
cure
blindness
diseases
today
announced
entered
agreement
kemwell
biopharma
pvt
kemwell
manufacture
ocugen
novel
biologic
product
candidate
preclinical
development
treating
severely
diseases
like
diabetic
macular
edema
dme
diabetic
retinopathy
dr
wet
macular
degeneration
agreement
kemwell
manage
cmc
clinical
manufacturing
activities
well
provide
supplies
toxicology
studies
phase
clinical
trials
kemwell
offers
proven
expertise
supporting
companies
process
development
clinical
commercial
manufacturing
biologicals
facilities
located
bangalore
india
biological
manufacturing
critical
phase
clinical
trials
partnership
paves
way
us
potentially
enter
clinic
planned
picking
cmo
commercial
capabilities
goal
ensuring
product
consistency
throughout
development
minimizing
regulatory
issues
drive
development
said
shankar
musunuri
chairman
ceo
delighted
partner
ocugen
advance
portfolio
transformative
therapies
cure
blindness
diseases
believe
expertise
process
development
manufacturing
solutions
play
critical
role
advance
clinic
could
deliver
hope
patients
severely
diseases
respond
currently
available
therapies
said
anurag
bagaria
chairman
ceo
kemwell
ocugen
planning
initiate
studies
including
glp
toxicology
studies
next
year
dme
first
targeted
indication
company
plans
advance
phase
trials
based
early
clinical
success
dme
company
undertake
evaluation
broader
indications
dr
us
alone
million
patients
struggle
retinal
diseases
approximately
patients
respond
current
therapies
including
treatments
patient
population
represents
significant
underserved
population
looking
new
therapies
distinct
method
action
compared
current
therapies
potential
drug
based
vivo
vitro
preclinical
studies
date
biologic
product
candidate
preclinical
development
treating
severely
diseases
like
diabetic
macular
edema
dme
diabetic
retinopathy
dr
wet
macular
degeneration
patients
affected
diseases
share
common
symptoms
blurriness
vision
progressive
vision
loss
disease
progresses
formation
fragile
leaky
new
blood
vessels
leads
fluid
accumulation
around
retina
causing
damage
vision
novel
fusion
protein
consisting
two
human
proteins
tumstatin
transferrin
already
present
normally
retinal
tissues
possesses
unique
features
enable
efficiently
target
leaky
blood
vessels
b
regress
existing
abnormal
blood
vessels
c
inhibit
growth
new
blood
vessels
retina
choroid
tumstatin
acts
agent
active
component
binds
integrin
receptors
play
crucial
role
disease
pathogenesis
transferrin
facilitates
targeted
delivery
tumstatin
retina
choroid
potentially
helps
increase
interaction
tumstatin
integrin
receptors
ocugen
ocugen
biopharmaceutical
company
focused
discovering
developing
commercializing
transformative
therapies
cure
blindness
diseases
breakthrough
modifier
gene
therapy
platform
potential
treat
multiple
retinal
diseases
one
drug
one
many
novel
biologic
product
candidate
aims
offer
better
therapy
patients
underserved
diseases
wet
macular
degeneration
diabetic
macular
edema
diabetic
retinopathy
information
please
visit
kemwell
biopharma
pvt
kemwell
leading
biologics
cdmo
asia
provides
services
global
biopharmaceutical
organizations
clinical
commercial
needs
kemwell
located
bangalore
india
provides
customers
high
quality
access
technology
development
manufacturing
mammalian
cell
products
kemwell
facilities
consists
cgmp
drug
substance
manufacturing
suites
bioreactor
capacity
sterile
fill
finish
line
cgmp
drug
product
manufacturing
development
laboratories
support
process
analytical
development
production
protein
therapeutics
monoclonal
antibodies
antibodies
fusion
proteins
information
please
visit
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
subject
risks
uncertainties
may
cases
use
terms
predicts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
current
expectations
risks
uncertainties
fully
described
periodic
filings
securities
exchange
commission
sec
including
risk
factors
described
section
entitled
risk
factors
quarterly
annual
reports
file
sec
statements
make
press
release
speak
date
press
release
except
required
law
assume
obligation
update
statements
contained
press
release
whether
result
new
information
future
events
otherwise
date
press
release
corporate
contact
ocugen
sanjay
subramanian
chief
financial
officer
ir
media
contact
lavoiehealthscience
katie
gallagher
kgallagher
